Top 5 Drug Type | Count |
---|---|
Small molecule drug | 10 |
Monoclonal antibody | 4 |
Chemical drugs | 1 |
Target |
Mechanism PD-1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date25 Aug 2021 |
Target |
Mechanism TIGIT inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism A2aR antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2024 |
Sponsor / Collaborator Columbia University [+1] |
Start Date08 Mar 2024 |
Sponsor / Collaborator |
Start Date25 Jan 2024 |
Sponsor / Collaborator Exelixis, Inc. [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Domvanalimab ( TIGIT ) | Advanced Gastric Adenocarcinoma More | Phase 3 |
Zimberelimab ( PD-1 ) | Advanced Gastric Adenocarcinoma More | Phase 3 |
Etrumadenant ( A2aR x A2bR ) | PD-L1 positive Non-Small Cell Lung Cancer More | Phase 2 |
AB-308 ( TIGIT ) | Advanced Malignant Solid Neoplasm More | Phase 1 |
AB-598 ( CD39 ) | Non-Small Cell Lung Cancer More | Phase 1 |